|
Originally published In Press as doi:10.1074/jbc.M109154200 on November 7, 2001
J. Biol. Chem., Vol. 277, Issue 4, 2505-2510, January 25, 2002
Transport Activity and Surface Expression of the
Na+-Ca2+ Exchanger NCX1 Are Inhibited by the
Immunosuppressive Agent Cyclosporin A and by the Nonimmunosuppressive
Agent PSC833*
Chava
Kimchi-Sarfaty ,
Judith
Kasir§,
Suresh V.
Ambudkar , and
Hannah
Rahamimoff §¶
From the Laboratory of Cell Biology, Center for
Cancer Research, NCI, National Institutes of Health, Bethesda, Maryland
20892-4255 and § Department of Biochemistry, Hebrew
University-Hadassah Medical School, Jerusalem 91120, Israel
Received for publication, September 21, 2001, and in revised form, November 7, 2001
 |
ABSTRACT |
Cyclosporin A (CsA) treatment of HEK 293 cells
expressing the rat heart RHE-1 (NCX1.1, EMBL accession number X68191)
or the rat brain RBE-2 (NCX1.5, GenBankTM accession number
X68813) Na+-Ca2+ exchanger
inhibited their transport activity in a
concentration-dependent manner. The inhibition was
detectable at 2 µM CsA, and exposure of the cells to 20 µM CsA resulted in a decrease of the
Na+-dependent Ca2+ uptake to about
20% relative to that of untreated cells. Determination of the surface
expression of the exchanger protein revealed a parallel
concentration-dependent reduction in the amount of the immunoreactive protein. No reduction was detected in the amount of
total immunoreactive exchanger protein in CsA-treated cells relative to
untreated ones. Among the different drugs tested, only PSC833, an
analog of cyclosporin D, mimicked the effects of CsA. Exposure of the
transfected cells to the chemically related cyclosporin D and macrolide
drugs (FK506 or rapamycin) had no effect on the transport activity or
the surface expression of the Na+-Ca2+
exchanger. Co-expression of the human multidrug transporter
P-glycoprotein (of which both drugs are modulators) with the cloned
Na+-Ca2+ exchanger revealed that transport
activity and surface expression of each transporter in the
co-transfected system were similar to those of each transporter alone
in both the presence and absence of CsA or PSC833. CsA and PSC833
inhibited the surface expression of the NCX1 protein but did not alter
the surface expression of P-glycoprotein. Unlike some P-glycoprotein
endoplasmic reticulum-retained mutants (Loo, T. W., and Clarke,
D. M. (1997) J. Biol. Chem. 272, 709-712), CsA
did not rescue RBE-2/F913 Stop, an endoplasmic reticulum-retained function-competent mutant of the Na+-Ca2+
exchanger (Kasir, J., Ren, X., Furman, I., and Rahamimoff, H. (1999)
J. Biol. Chem. 274, 24873-24880) and did not
induce its kinesis to the surface membrane, further demonstrating
molecular differences between P-glycoprotein and NCX1 mutants for
interaction with CsA.
 |
INTRODUCTION |
Ca2+ ions regulate a wide spectrum of cellular
processes such as signal transduction, neurotransmitter release, muscle
contraction, transcription, and many others (1). Ca2+
signaling involves a rapid rise in free intracellular Ca2+
levels for brief periods of time, followed by a decrease and restoration of the low cytosolic resting Ca2+ levels. Among
the different Ca2+ transporters present in the plasma
membrane and intracellular organelles, the electrogenic
Na+-Ca2+ exchanger plays a major and unique
role in the regulation of cell [Ca2+] for two reasons: it
can move Ca2+ across the membrane bidirectionally,
depending on the net electrochemical driving force, and it has a very
high turnover rate (2). Although the Na+-Ca2+
exchanger is expressed in most mammalian cell types, it is of especially high density in excitable tissues such as the heart, in
smooth cells, and in the brain (2).
Cyclosporin A (CsA)1 is an
immunosuppressive drug that is widely used against graft rejection (3).
Among the complications that accompany CsA treatment of transplant
patients are hypertension (4) and nephrotoxicity (3), both of which can
be linked to impaired Ca2+ homeostasis, an increase in
intracellular Ca2+, and smooth muscle vasoconstriction
(5).
In this work, we have studied the effects of CsA on the functional
expression of the Na+-Ca2+ exchanger NCX1 to
examine its possible involvement in CsA-related posttransplant
complications. We show that treatment of cells expressing the
Na+-Ca2+ exchanger with CsA or with the
nonimmunosuppressant PSC833 (6), which is an analog of weakly
immunosuppressant cyclosporin D (CsD) (7), results in a
concentration-dependent inhibition of
Na+-Ca2+ exchange activity and a corresponding
decrease in surface expression of the protein. The effects are probably
posttranslational because no significant differences in the amount of
total immunoreactive protein derived from the
Na+-Ca2+ exchanger are detected between cells
expressing the transporter without and with CsA treatment. Other
immunosuppressive agents such as FK506 and rapamycin (8) had no effect
on either transport activity or surface expression of the
Na+-Ca2+ exchanger. Similar results are found
in cells expressing both the Na+-Ca2+ exchanger
and P-glycoprotein (P-gp), with which CsA and PSC833 directly interact
and function as modulator (9).
 |
EXPERIMENTAL PROCEDURES |
Expression Systems
HEK 293 cells (ATCC 1573) were used to express the cloned (in
pcDNA3.1) Na+-Ca2+ exchangers
rbe-2/NCX1.5 (10), rhe-1/NCX1.1 (11), their
mutants, and the cloned MDR1 (kindly given by Dr. Y. Zhou).
Preparation of amino-terminal FLAG-tagged RBE-2
(fn-rbe-2) has been described previously (12, 13). To
prepare the amino-terminal FLAG-tagged rat heart
Na+-Ca2+ exchanger NCX1.1
(fn-rhe-1), an AgeI-Eco47III fragment
was excised from rhe-1 (11) and subcloned into
AgeI-Eco47III-digested fn-rbe-2 vector. The fidelity of the subcloning procedure has been verified by
sequencing. Transfection was carried out with LipofectAMINE Plus
reagent (Invitrogen) according to the protocol supplied by the
manufacturer. Two µg and 0.66 µg of pDNA were used to transfect cells plated into 60-mm dishes or 1 well of a 12-well plate,
respectively. CsA (Calbiochem-Novabiochem Corp, La Jolla, CA), FK506
(Alexis Corp.), CsD (a gift from Dr. Gilbert Burckhardt, University of Pittsburgh School of Pharmacy), PSC833 (a gift from Dr. S. Bates, National Cancer Institute, National Institutes of Health), and rapamycin (a gift from Drug Repository, National Cancer Institute, National Institutes of Health) were dissolved in Me2SO and
added 3 h after transfection together with the 10% fetal calf
serum-Dulbecco's modified Eagle's medium supplement to the
transfected cells (Invitrogen). The experiments were repeated three to
five times. Transport measurements were done in triplicate. In each
experiment, the transport activity of rbe-2- or
rhe-1-transfected cells with Me2SO treatment was taken as 100%, and the transport activities measured in the
drug-treated cells were calculated in relative values. Some of the
experiments were also repeated by using the VTF-7/HeLa cell expression
system (14, 15).
Determination of Na+-dependent
Ca2+ Uptake
Determination of transport activity in whole cells was carried
out exactly as described previously (10-13, 16). In principle, transfected cells were preloaded with 0.16 M NaCl
and 0.01 M Tris-HCl, pH 7.4, using 25 µM
nystatin (Sigma). Cells were washed with the same buffered NaCl
solution (without MgCl2) to remove nystatin. Transport was
initiated by overlaying the cells with the same buffered
Na+- or K+-containing solution, to which 25 µM 45Ca2+ was added. All
solutions also contained 1 mM ouabain (Sigma). Na+-dependent Ca2+ uptake was
determined by subtracting the Ca2+ taken up in the absence
of a Na+ gradient from that taken up in its presence.
Determination of P-glycoprotein Pump Activity by Rhodamine 123 Dye Efflux Assay
P-gp pump activity was determined as described in Ref. 17.
Transfected cells were equilibrated with a 150 ng/ml solution of
rhodamine 123 in Iscove's modified Dulbecco's modified Eagle's medium-5% fetal calf serum for 20 min at 37 °C. After washing the
cells with phosphate-buffered saline and 0.1% bovine serum albumin,
the dye was allowed to efflux for 2 h at 37 °C. As a control
for pump activity, the cells were preincubated with the P-gp inhibitor
(reversing agent) verapamil (5 µM; Sigma) for 30 min
before and during both rhodamine 123 staining and the efflux phase of
the assay. Immediately afterward, the cells were analyzed by FACSort
flow cytometer using CellQuest software (Becton Dickinson, Mountain
View, CA).
Measuring Surface Expression of the
Na+-Ca2+ Exchanger and
P-glycoprotein by FACS Analysis
NCX1 Isoforms--
Cells expressing the extracellular (12, 13)
amino-terminal FLAG-tagged isoforms of the NCX1 gene were used to
determine surface expression of the Na+-Ca2+
exchanger. As described previously, the FLAG epitope was
introduced into the extracellular amino-terminal "tail" of the
protein after Gly8 (instead of Asn9, the single
glycosylation site of the protein), and it was accessible to externally
added antibody without any permeabilization. Introduction of the
epitope had no effect on the functional expression of the protein (12,
13, 18).
For FACS analysis (19), 105 cells were washed and
resuspended in 200 µl of Iscove's modified Dulbecco's modified
Eagle's medium-5% fetal calf serum and 1 µg of mouse M2 (anti-FLAG)
monoclonal antibody (Sigma) or control mouse IgG1 antibody (BD
PharMingen, San Jose, CA) for 30 min at 37 °C. As a secondary
antibody, 1 µg of fluorescein isothiocyanate-conjugated anti-mouse
antibody IgG1 (BD PharMingen) was used. Cells were washed with
phosphate-buffered saline and 0.1% bovine serum albumin and analyzed
by FACS analysis (see above).
Median value was determined using CellQuest software (Becton Dickinson)
histogram stat analysis for each curve. The average of two median
fluorescence values (in arbitrary units) for similar curves from two
independent experiments is presented under "Results."
For determination of the total amount of immunoreactive NCX1 protein,
the cells were permeabilized before application of the primary antibody
M2 or the control antibody using the IntraPrep permeabilization reagent
(Immunotech, Marseille, France).
P-gp (Human)--
To determine the surface expression of P-gp,
MRK16 (a gift from Hoechst, Kawago City, Saitama, Japan), a monoclonal
antibody against an external epitope of P-gp (20), was used. 1 µg of MRK16 or 5 µg of an isotype control antibody (IgG2a) was added to the
washed cells in 200 µl of Iscove's modified Dulbecco's modified
Eagle's medium and incubated at 37 °C for 20 min. As a secondary
antibody, 1 µg of fluorescein isothiocyanate-conjugated anti-mouse
IgG2 (BD PharMingen) was used.
Western Analysis
HEK 293 cells were lysed with M-Per mammalian protein extraction
reagent (Pierce), to which 1 mM dithiothreitol and the
following protease inhibitors were added: aprotinin (Sigma), 17 µg/ml; leupeptin (Sigma), 2 µg/ml; pepstatin (Sigma), 2 µg/ml;
and AEBSF (4-(2-aminoethyl)benzenesulfonyl fluoride)
(Sigma), 1 mM. SDS-PAGE was carried out by standard procedures (21) using either 10% or 4-20% gradient precast
polyacrylamide gels (Invitrogen). The following antibodies were used at
a dilution of 1:1000 for Western blot analysis: anti-cyclophilin A
(Calbiochem-Novabiochem Corp.), anti-FKBP59/HSP56
(Calbiochem-Novabiochem Corp.), anti-cyclophilin B (Affinity
BioReagents, Golden, CO), and anti-FKBP12 (Affinity BioReagents).
Detection of the antigen-antibody complexes was done with horseradish
peroxidase-conjugated anti-rabbit or anti-mouse secondary antibodies
(Invitrogen) using ECL reagents purchased from Amersham Biosciences,
Inc. or Pierce. NCX1 isoform-expressing HEK 293 cells were treated with
or without CsA and analyzed similarly by Western blot. For
analysis of total cell extracts, 30 µg of cell protein derived from a
single well of a 12-well plate was used. Phenylmethylsulfonyl fluoride
(0.1 µM), leupeptin (10 µg/ml), and pepstatin (10 µg/ml) were added to the cells before solubilization. To detect the
level of Na+-Ca2+ exchanger protein AbO-8, a
polyclonal antibody directed against a pentadecapeptide corresponding
to amino acids 649-663 of the rat heart exchanger was used (12).
Preparation, testing, and purification of the antibodies were done as
described previously (12, 16). Goat anti-rabbit horseradish
peroxidase-conjugated secondary antibody (Jackson ImmunoResearch
Laboratories, Inc., West Grove, PA) was used to detect
antigen-antibody complexes with the Amersham Biosciences, Inc. ECL kit.
 |
RESULTS |
CsA Inhibits the Transport Activity and the Surface Expression of
the Na+-Ca2+ Exchanger NCX1--
To examine
the effects of CsA on the Na+-Ca2+ exchanger,
we have transfected HEK 293 cells with fn-rbe-2 or
fn-rhe-1, two rat isoforms of the NCX1 gene. The transfected
cells were exposed to 2-20 µM CsA or an equal volume of
Me2SO (which never exceeded 1% of the assay volume), and
Na+-dependent Ca2+ uptake was
determined 24 h after transfection, as described under "Experimental Procedures." Fig. 1
summarizes the results of these experiments. It can be seen that
exposure of the cells expressing the rat heart exchanger RHE-1 ( ) or
the rat brain exchanger RBE-2 ( ) to CsA results in inhibition of
Na+-dependent Ca2+ uptake in a
concentration-dependent manner. Inhibition of
Na+-dependent Ca2+ uptake could be
detected at 2 µM CsA. Exposure of the cells expressing the transporter to 20 µM CsA resulted in a decrease of
transport activity to about 20% relative to that expressed in the
absence of the drug. Higher concentrations of CsA could not be tested in transport experiments because at concentrations above 20 µM, the numerous washes included in the experimental
protocol led to excessive cell peeling from the adherent surfaces. CsA
had no effect on the transport assay itself because addition of the drug to the solutions used for the assay (but not to the
transporter-expressing cells) did not result in a decrease in
the Na+-dependent Ca2+ uptake (data
not shown).

View larger version (15K):
[in this window]
[in a new window]
|
Fig. 1.
The effect of different concentrations of CsA
on Na+-dependent Ca2+
uptake in HEK 293 cells expressing the rat heart and rat brain
isoforms of the NCX1 gene. Cells were transfected with plasmids
encoding the rat heart Na+-Ca2+ exchanger
fn-rhe-1 ( ) and the rat brain
Na+-Ca2+ exchanger fn-rbe-2 ( ).
Na+-dependent Ca2+ uptake was
determined 24 h after transfection as described under
"Experimental Procedures" without and with exposure of the
isoform-expressing cells to different concentrations of CsA.
|
|
To study the effects of CsA on the surface and total expression of the
Na+-Ca2+ exchanger NCX1, HEK 293 cells were
transfected with the cloned amino-terminal FLAG-tagged
Na+-Ca2+ exchangers. Surface expression was
determined by measuring the fluorescence intensity using FACS analysis
(for details, see "Experimental Procedures"). Cells were labeled
with the monoclonal anti-FLAG M2 antibody or the control IgG1
antibody as primary antibodies. Fluorescein isothiocyanate-conjugated
anti-mouse antibody was used as the secondary antibody. The total
amount of immunoreactive Na+-Ca2+ exchanger
protein in transfected cells was analyzed in a similar manner, except
that the cells were permeabilized prior to application of the primary
antibody or the control antibody.
Fig. 2, A D, shows the
surface expression of the Na+-Ca2+ exchanger
FN-RBE-2 without (Fig. 2A) and with application of 0.1 (Fig. 2B), 10 (Fig. 2C), and 20 µM (Fig.
2D) CsA. It can be seen that the fluorescence of M2
antibody-labeled cells decreases in a
concentration-dependent manner that parallels the decrease
of transport activity (Fig. 1). The two population peaks shown in Fig.
2, A D, represent the nontransfected cells (left
peak, lower level of fluorescence) and the transfected cells
(right peak). Although the efficiency of transfection might
vary somewhat from dish to dish, in this experiment it did not change
significantly, and there is no change in the extent of left peak, the
population of cells exhibiting a lower level of fluorescence
(nontransfected cells). CsA treatment changed only the surface
expression of the exchanger protein, which is demonstrated by the
change in fluorescence of the right peak (the population of transfected
cells). Similar results were also obtained when FN-RHE-1 was expressed
in HEK 293 cells (data not shown). We have also examined the effect of
CsA on the amount of total immunoreactive
Na+-Ca2+ exchanger protein. The total amount of
immunoreactive protein detected in transfected cells did not change
significantly when these cells were treated with 2-50 µM
CsA. Fig. 3 shows the total exchanger
protein expression detected by AbO-8, a polyclonal antibody directed
against a pentadecapeptide corresponding to amino acids 649-663 of the
rat heart exchanger (12). The same amount of protein (30 µg) was
loaded in each lane. All transfections were done in parallel.
Lane A shows control, fn-rbe-2-transfected cells, and lanes B F show transfected cells exposed to 2, 5, 10, 20, and 50 µM CsA, respectively. Similar results were
obtained when FACS analysis was used to detect the total amount of
exchanger protein. The control antibody curve reveals an average median fluorescence (in arbitrary units) of 27.52. The average median value
for M2 binding is 243.71 arbitrary units, whereas treatment of the
cells with 10 µM CsA did not change significantly the
median fluorescence value of M2 binding (229.79 arbitrary units). The inhibitory effects of CsA on the transport activity and surface expression of the Na+-Ca2+ exchanger were not
restricted to the HEK 293 expression system. Similar results were
obtained when we expressed the cloned NCX1 gene in the recombinant
vaccinia virus VTF-7/HeLa cell expression system (data not shown).

View larger version (32K):
[in this window]
[in a new window]
|
Fig. 2.
The effect of different concentrations of CsA
on the surface expression of the rat brain
Na+-Ca2+ exchanger expressed in HEK 293 cells. Cells expressing the Na+-Ca2+
exchanger FN-RBE-2 were incubated with various concentrations of CsA or
Me2SO. 24 h after transfection, the cells were
analyzed for cell surface expression using M2 (the anti-FLAG antibody)
or IgG1 control antibody. A, transfected cells
treated with Me2SO only. Control antibody ( ), M2
antibody (. . . . . . . . . . ). B,
transfected cells treated with 0.1 µM CsA.
C, transfected cells treated with 10 µM
CsA. D, transfected cells treated with 20 µM
CSA.
|
|

View larger version (33K):
[in this window]
[in a new window]
|
Fig. 3.
Western analysis of HEK 293 cells expressing
the Na+-Ca2+ exchanger protein without and with
exposure to CsA. Protein derived from cells expressing FN-RBE-2
(lane A) or FN-RBE-2 after exposure to 2 (lane
B), 5 (lane C), 10 (lane D), 20 (lane
E), and 50 µM (lane F) CsA was separated
by SDS-PAGE. 30 µg of protein derived from a single well of a 12-well
plate was loaded in each lane. The polyclonal antibody AbO-8 (see
"Experimental Procedures") was used for Western blot analysis.
Horseradish peroxidase-conjugated goat anti-rabbit antibody was used to
detect antigen-antibody complexes by ECL.
|
|
Not All Structurally Related Undecapeptide Analogues of CsA Inhibit
Na+-Ca2+ Exchanger
Transport Activity and Surface Expression--
To examine whether the
inhibitory effects of CsA on the Na+-Ca2+
exchanger are linked to its immunosuppressive properties, we have
determined the effect of the weakly immunosuppressive analogue, CsD,
and the nonimmunosuppressant analogue of CsD, PSC833, on the transport
activity and the surface and total expression of the
Na+-Ca2+ exchanger. CsD, added to transfected
HEK 293 cells at concentrations of 5-50 µM, had no
effect on Na+ gradient-dependent
Ca2+ uptake, on the surface expression, and on the total
amount of immunoreactive exchanger protein of both FN-RBE-2 and
FN-RHE-1 (data not shown).
However, exposure of the transfected cells to PSC833 resulted in a
concentration-dependent reduction in transport activity and
surface expression. Fig. 4 shows the
effect of 3-10 µM PSC833 on Na+ gradient
Ca2+ uptake of the rat heart exchanger RHE-1 expressed in
HEK 293 cells. The surface expression pattern in transfected cells
exposed or not exposed to 10 µM PSC833 paralleled the
transport data: control antibody curve reveals an average median of
45.68 arbitrary units. Average median value for surface M2 binding is
436.15 arbitrary units, whereas treatment of the cells with 10 µM PSC833 significantly changed the average median
fluorescence value of M2 binding (193.39 arbitrary units). The
corresponding amounts of total exchanger protein detected in
permeabilized cells without and with exposure of the cells to 10 µM PSC833 were similar: average median florescence values
of M2 binding were 268.0 and 225.26 arbitrary units, respectively (average median florescence value of control antibody binding is 115.23 arbitrary units). In a manner similar to CsA, PSC833 inhibited both the
transport activity and surface expression of the protein in a
concentration-dependent manner. No significant effects were
observed on the total amount of exchanger protein. Similar results were
also obtained when the rat brain isoform NCX1.5 was expressed.

View larger version (13K):
[in this window]
[in a new window]
|
Fig. 4.
The effect of different concentrations of
PSC833 on the Na+-Ca2+ exchange activity of
NCX1 expressed in HEK 293 cells. Cells were transfected
with the plasmid encoding the rat heart
Na+-Ca2+ exchanger fn-rhe-1.
Na+-dependent Ca2+ uptake was
determined 24 h after transfection as described under
"Experimental Procedures" without and with exposure of the NCX1.1
expressing cells to different concentrations of PSC833.
|
|
The Effects of the Immunosuppressants FK506 and Rapamycin on the
Transport Activity and Surface Expression of the
Na+-Ca2+
Exchanger--
To elucidate the cellular processes responsible
for the effects of CsA on transport activity and surface expression of
the Na+-Ca2+ exchanger, we exposed cells
expressing the NCX1 or NCX1.5 gene products to FK506 (5-50
µM) and to rapamycin (2-50 µM). These drugs had no effect on the transport activity, surface expression, and
total amount of exchanger protein expressed in transfected cells (data
not shown). Similarly, exposure of transfected cells to rapamycin had
no effect on Na+-dependent Ca2+
uptake, surface expression, or total expression of the
Na+-Ca2+ exchanger (data not shown).
The Effects of CsA on Transport Activities and Surface Expression
of P-glycoprotein and NCX1 Co-expressed in HEK 293 Cells--
Because
CsA and PSC833 are substrates of P-gp and are used as reversal agents
to combat drug resistance in cancer cells (9), it was of interest to
examine whether the effects of CsA and PSC833 on the transport activity
and surface expression of the Na+-Ca2+
exchanger persist when HEK 293 cells are also co-transfected with both
the cloned fn-rbe-2 and MDR1 genes. According to
MRK16 and M2 monoclonal antibody staining (Fig.
5, B and C), a
large majority of the transfected cells express both proteins.

View larger version (21K):
[in this window]
[in a new window]
|
Fig. 5.
Assessment of the transport function and
surface expression of P-gp and RBE in P-gp- and/or RBE-2-expressing
cells. A, 24 h after transfection, cells were
harvested, washed, and loaded for 20 min with 150 ng/ml rhodamine 123, after which efflux was initiated for 2 h. The transport of
rhodamine 123-transfected HEK 293 cells was determined by FACS
analysis. Cells were transfected with fn-rbe-2 only
(control) ( ), transfected with MDR1 only
(-.-.-.-),
or co-transfected with MDR1 and fn-rbe-2
(. . . . . . . . . . ). B, 24 h
after transfection, the cells were analyzed for surface expression
using MRK16 antibody or IgG2a control antibody. Cells expressed
FN-RBE-2 only ( ), P-gp and FN-RBE-2 (. . . . . . . . . .
), or P-gp only
(-.-.-.-).
C, control IgG1 antibody staining of cells treated with
10 µM CsA ( ), M2 antibody staining of P-gp- and
FN-RBE-2-expressing cells treated with Me2SO only
(. . . . . . . . . . ), M2 antibody staining of P-gp- and
FN-RBE-2-expressing cells treated with 10 µM CsA
(-.-.-.-),
M2 antibody staining of FN-RBE-2-expressing cells treated with 10 µM CsA (-..-..-).
|
|
The transport activity of FN-RBE-2 and P-gp was determined in cells
transfected separately with each transporter and in co-transfected cells, without and with CsA. Na+-dependent
Ca2+ uptake in the absence and presence of 10 µM CsA was similar in fn-rbe-2-transfected
cells and in cells co-transfected with fn-rbe-2 and
MDR1. The relative transport activity in cells exposed to 10 µM CsA was 28.7% (S.D. = 3.92%) and 36.12% (S.D. = 5.88%), respectively. RBE-2 expression did not change the activity of P-gp (using rhodamine 123 dye) in the absence (Fig. 5A) or
presence (data not shown) of CsA. MRK16 and M2 staining revealed the
same pattern: the surface expression of P-gp was not changed by
co-transfection of fn-rbe-2 with the MDR1 (Fig.
5B). The surface expression of RBE-2 was similar in cells
expressing this protein alone and in cells co-expressing this protein
with P-gp. CsA inhibited the surface expression of RBE-2, regardless of
whether RBE-2 was expressed alone or with P-gp (Fig.
5C). MRK16 staining of P-glycoprotein-expressing cells was not altered by CsA treatment. The curve of MRK16 binding reveals a median fluorescence of 154.78 arbitrary units. Treatment of
the cells with 10 µM CsA did not significantly change the
median fluorescence value of MRK16 binding (155.06 arbitrary units).
Can CsA Modulate the Kinesis of Surface Expression-incompetent
Mutants of the Na+-Ca2+
Exchanger?--
We have also explored the possibility that application
of CsA might correct the kinesis to the surface membrane of some
ER-retained mutants of the Na+-Ca2+ exchanger
in a manner similar to its effect on ER-retained maturation-impaired mutants of P-glycoprotein (22). FN-C13
(fn-rbe-2/F913 Stop), a FLAG epitope-tagged
carboxyl-terminal-truncated, surface expression-incompetent mutant of
RBE-2 (13), was expressed in HEK 293 cells (without and with CsA
treatment). No transport activity was detected in whole HEK 293 cells
transfected with FN-C13 without or with exposure of the transfected
cells to 5-20 µM CsA (data not shown). No surface expression of FN-C13 was detected in the transfected cells without or
with 5-20 µM CsA treatment (data not shown). The
fluorescence intensity that was measured using control antibody
overlapped the fluorescence intensity obtained by M2 binding to the
cells that were not treated or treated with different concentrations of
CsA, suggesting that the drug did not induce surface expression of this
mutant protein.
Expression of Target Immunophilins in HEK 293 Cells--
To assess
whether the differences in sensitivity of
Na+-Ca2+ exchanger NCX1 expressed in HEK 293 cells to CsA and FK506 resulted from differences in expression pattern
of the respective immunophilin targets, we carried out Western blot
analysis of HEK 293 cell extracts using antibodies against cyclophilin
A (CyPA18), cyclophilin B (CyPB21), FKBP12, and FKBP59. All the
immunophilins tested were expressed in HEK 293 cells before and after
transfection (with the plasmid vector or the cloned
fn-rbe-2), without and with CsA treatment (data not shown).
 |
DISCUSSION |
In this work, we have shown that CsA inhibited in a
concentration-dependent manner the transport activity and
surface expression of the rat heart and rat brain isoforms of
Na+-Ca2+ exchanger NCX1 expressed in HEK 293 cells. CsA did not reduce the specific transport activity of the
surface-expressed Na+-Ca2+ exchanger because
addition of the drug to the assay rather than to the transfected cells
did not have any effect on Na+-Ca2+ exchange
activity. Moreover, immunofluorescence studies of CsA-treated cells
clearly demonstrated a significant decrease in the amount of
surface-expressed protein. Among the different drugs that we tested,
only the nonimmunosuppressive PSC833 (23-25) mimicked the effects of
CsA. The weakly immunosuppressive CsD (7), which is chemically related
to both CsA and PSC833 (6), and the two macrolides, FK506 and
rapamycin, had no detectable effect on transport activity and surface
expression of the Na+-Ca2+ exchanger, although
we exposed the NCX1-expressing cells to concentrations as high
as 50 µM. The effects of CsA and PSC833 on the surface expression of the Na+-Ca2+ exchanger expressed
transiently in HEK 293 cells are probably posttranslational and do not
involve calcineurin-dependent transcriptional regulation
(26). Several lines of evidence support this hypothesis. First, the
total amount of Na+-Ca2+ exchanger protein
expressed in CsA- and PSC833-treated cells was similar to the amount of
immunoreactive exchanger protein detected in untreated cells. Second,
surface expression was reduced by both the immunosuppressive CsA and
the nonimmunosuppressive PSC833. Third, it was recently shown
(27) that calcineurin is not involved in developmental regulation of
transcription of NCX1 and NCX3 gene products in cerebellar granule
cells. Fourth, the concentrations of CsA that inhibit
calcineurin-mediated transcriptional regulatory effects are in the
nanomolar range (26), whereas a micromolar range of CsA was required to
inhibit transport activity and surface expression of the
Na+-Ca2+ exchanger.
The ubiquitously expressed immunophilins, the cyclophilins and the
FKBPs (8, 28), are involved in protein folding in at least two
ways: catalysis of the rate-limiting (29) isomerization of imide
peptide bonds preceding prolines via their peptidyl prolyl cis-trans
isomerase domain and chaperone activity via their conserved protein
binding domain (8, 30, 31). "Quality control" of newly synthesized
secretary and membrane proteins takes place in the ER. The process
ensures that only mature and properly folded proteins reach their
target destination. Misfolded and immature proteins are retained in the
ER and subsequently degraded (32). Because both immunosuppressive CsA
and nonimmunosuppressive PSC833 inhibit the surface expression of the
Na+-Ca2+ exchanger NCX1 posttranslationally,
the involvement of their cyclophilin targets in the folding of the
exchanger protein is implied.
We do not know at present whether this is mediated by inhibition of the
peptidyl prolyl cis-trans isomerase activity of cyclophilin A
(cytosolic) or B (ER-resident) (8), inactivation of the chaperone-like activity of cyclophilin A or B (28), or both activities in concert. Each of these could provide a plausible explanation for the reduction of surface expression and transport activity of the
Na+-Ca2+ exchanger NCX1.
Surface expression reduction by immunosuppressive CsA but not
SDZ-211-811, its nonimmunosuppressive analogue, was demonstrated for
the homo-oligomeric acetylcholine receptor containing the 7 subunit
and the homo-oligomeric 5-hydroxytryptamine type 3 receptor expressed
in Xenopus oocytes (33, 34). The effect could be reversed by
overexpression of exogenous rat brain cyclophilin but not by expression
of cyclophilin bearing a mutation within the peptidyl prolyl cis-trans
isomerase domain. Reduction of surface expression by CsA was also
reported for the Kir2.1 potassium channel (35), the creatinine
transporter (36), and the insulin receptor (37). Like the
homo-oligomeric acetylcholine and 5-hydroxytryptamine receptors (33)
and the creatinine transporter (36), but unlike the insulin receptor
(37) and the Kir2.1 potassium channel (35), the
Na+-Ca2+ exchanger studied in this work was not
sensitive to micromolar concentrations of FK506 treatment of the
NCX1-expressing cells. Because FKBP12 and FKBP59 are expressed
in HEK 293 cells, the absence of these two target immunophilins is not
responsible for the insensitivity of our system to this
immunosuppressant. It is interesting that surface expression of
Na+ channels in adrenal chromaffin cells was up-regulated
by all three drugs (CsA, FK506, and rapamycin) (38).
At drug concentrations (6, 9, 41, 42) similar to those used in this
study, CsA is commonly used in transplant patients to protect against
graft rejection, and PSC833 is used as a reversal agent for
up-regulated P-gp (39, 40) in cancer cells. Reduction of surface
expression by CsA and PSC833 of the Na+-Ca2+
exchanger NCX1, by the same or a different pathway, might have considerable effects on cellular Ca2+ homeostasis in view
of the transporters' major role in the regulation of cell
Ca2+ ion concentration. Based on the changing membrane
potential values, the Na+-Ca2+ exchanger is
involved in both Ca2+ extrusion and Ca2+ influx
(2). Its reduced surface expression can lead to increased intracellular
Ca2+ levels in resting cells. It can also result in reduced
Ca2+ influx in above reversal potential-depolarized cells,
which is of importance in the heart (2). Both CsA and PSC833 were shown to cross the blood-brain barrier (43, 44). They were shown in neuronal
cells to be highly neurotoxic (45, 46). The
Na+-Ca2+ exchangers NCX1, NCX2, and NCX3 have
about 65% structural homology (47-49). Their proline residues are
highly conserved. Whether the actions of CsA and PSC833 are mediated by
inhibition of the peptidyl prolyl cis-trans isomerase activity of
cyclophilin or by its chaperone-like activity, the surface expression
of the three gene products might be affected by exposure of the
Na+-Ca2+ exchanger-expressing cells to
CsA or PSC833. However, further research has to be done, both in
heterologous expression systems and in cells endogenously expressing
the Na+-Ca2+ exchangers, to elucidate the
mechanism of action of CsA and PSC833 on modulation of cell surface
expression of the Na+-Ca2+ exchanger protein.
 |
ACKNOWLEDGEMENTS |
We thank Dr. Michael M. Gottesman for support
throughout this work, helpful suggestions, and critical reading of the
manuscript. We also thank Dr. Gilbert Burckhardt (University of
Pittsburgh School of Pharmacy) for the gift of cyclosporin D.
 |
FOOTNOTES |
*
The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
¶
To whom correspondence should be addressed: Dept. of
Biochemistry, Hebrew University-Hadassah Medical School, P. O. Box
12272, Jerusalem 91120, Israel. Tel.: 972-2-6758511; Fax:
972-2-6784010; E-mail: Hannah@cc.huji.ac.il.
Published, JBC Papers in Press, November 7, 2001, DOI 10.1074/jbc.M109154200
 |
ABBREVIATIONS |
The abbreviations used are:
CsA, cyclosporin A;
CsD, cyclosporin D;
FN, amino-terminal FLAG-tagged;
P-gp, P-glycoprotein;
ER, endoplasmic reticulum;
FACS, fluorescence-activated
cell-sorting;
FKBP, FK506-binding protein.
 |
REFERENCES |
| 1.
|
Carafoli, E.,
and Klee, C.
(1999)
Calcium as Cellular Regulator
, Vol. 1
, Oxford University Press Inc., Oxford
|
| 2.
|
Blaustein, M. P.,
and Lederer, W. J.
(1999)
Physiol. Rev.
79,
763-854
|
| 3.
|
Hariharan, S.,
Johnson, C. P.,
Bresnahan, B. A.,
Taranto, S. E.,
McIntosh, M. J.,
and Stablein, D.
(2000)
N. Engl. J. Med.
342,
605-612
|
| 4.
|
Scherrer, U.,
Vissing, S. F.,
Morgan, B. J.,
Rollins, J. A.,
Tindall, R. S.,
Ring, S.,
Hanson, P.,
Mohanty, P. K.,
and Victor, R. G.
(1990)
N. Engl. J. Med.
323,
693-699
|
| 5.
|
Frapier, J. M.,
Choby, C.,
Mangoni, M. E.,
Nargeot, J.,
Albat, B.,
and Richard, S.
(2001)
FEBS Lett.
493,
57-62
|
| 6.
|
Lush, R. M.,
Meadows, B.,
Fojo, A. T.,
Kalafsky, G.,
Smith, H. T.,
Bates, S.,
and Figg, W. D.
(1997)
J. Clin. Pharmacol.
37,
123-128
|
| 7.
|
Sadeg, N.,
Pham-Huy, C.,
Rucay, P.,
Righenzi, S.,
Halle-Pannenko, O.,
Claude, J. R.,
Bismuth, H.,
and Duc, H. T.
(1993)
Immunopharmacol. Immunotoxicol.
15,
163-177
|
| 8.
|
Marks, A. R.
(1996)
Physiol. Rev.
76,
631-649
|
| 9.
|
Smith, A. J.,
Mayer, U.,
Schinkel, A. H.,
and Borst, P.
(1998)
J. Natl. Cancer Inst.
90,
1161-1166
|
| 10.
|
Furman, I.,
Cook, O.,
Kasir, J.,
and Rahamimoff, H.
(1993)
FEBS Lett.
319,
105-109
|
| 11.
|
Low, W.,
Kasir, J.,
and Rahamimoff, H.
(1993)
FEBS Lett.
316,
63-67
|
| 12.
|
Cook, O.,
Low, W.,
and Rahamimoff, H.
(1998)
Biochim. Biophys. Acta
1371,
40-52
|
| 13.
|
Kasir, J.,
Ren, X.,
Furman, I.,
and Rahamimoff, H.
(1999)
J. Biol. Chem.
274,
24873-24880
|
| 14.
|
Blakely, R. D.,
Clark, J. A.,
Rudnick, G.,
and Amara, S. G.
(1991)
Anal. Biochem.
194,
302-308
|
| 15.
|
Fuerst, T.,
Niles, E.,
Studier, F.,
and Moss, B.
(1986)
Proc. Natl. Acad. Sci., U. S. A.
83,
8122-8126
|
| 16.
|
Furman, I.,
Cook, O.,
Kasir, J.,
Low, W.,
and Rahamimoff, H.
(1995)
J. Biol. Chem.
270,
19120-19127
|
| 17.
|
Rund, D.,
Dagan, M.,
Dalyot-Herman, N.,
Kimchi-Sarfaty, C.,
Schoenlein, P. V.,
Gottesman, M. M.,
and Oppenheim, A.
(1998)
Hum. Gene Ther.
9,
649-657
|
| 18.
|
Ren, X.,
Kasir, J.,
and Rahamimoff, H.
(2001)
J. Biol. Chem.
276,
9572-9579
|
| 19.
|
Zhou, Y.,
Gottesman, M. M.,
and Pastan, I.
(1999)
Mol. Pharmacol.
56,
997-1004
|
| 20.
|
Germann, U. A.,
Chambers, T. C.,
Ambudkar, S. V.,
Licht, T.,
Cardarelli, C. O.,
Pastan, I.,
and Gottesman, M. M.
(1996)
J. Biol. Chem.
271,
1708-1716
|
| 21.
|
Harlow, E.,
and Lane, D.
(1988)
Antibodies: A Laboratory Manual
, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
|
| 22.
|
Loo, T. W.,
and Clarke, D. M.
(1997)
J. Biol. Chem.
272,
709-712
|
| 23.
|
Sonneveld, P.,
Marie, J. P.,
Huisman, C.,
Vekhoff, A.,
Schoester, M.,
Faussat, A. M.,
van Kapel, J.,
Groenewegen, A.,
Charnick, S.,
Zittoun, R.,
and Lowenberg, B.
(1996)
Leukemia (Baltimore)
10,
1741-1750
|
| 24.
|
Archinal-Mattheis, A.,
Rzepka, R. W.,
Watanabe, T.,
Kokubu, N.,
Itoh, Y.,
Combates, N. J.,
Bair, K. W.,
and Cohen, D.
(1995)
Oncol. Res.
7,
603-610
|
| 25.
|
Boesch, D.,
Gaveriaux, C.,
Jachez, B.,
Pourtier-Manzanedo, A.,
Bollinger, P.,
and Loor, F.
(1991)
Cancer Res.
51,
4226-4233
|
| 26.
|
Liu, J.,
Farmer, J. D., Jr.,
Lane, W. S.,
Friedman, J.,
Weissman, I.,
and Schreiber, S. L.
(1991)
Cell
66,
807-815
|
| 27.
|
Li, L.,
Guerini, D.,
and Carafoli, E.
(2000)
J. Biol. Chem.
275,
20903-20910
|
| 28.
|
Ivery, M. T.
(2000)
Med. Res. Rev.
20,
452-484
|
| 29.
|
Brandts, J. F.,
Halvorson, H. R.,
and Brennan, M.
(1975)
Biochemistry
14,
4953-4963
|
| 30.
|
Schiene-Fischer, C.,
and Yu, C.
(2001)
FEBS Lett.
495,
1-6
|
| 31.
|
Gothel, S. F.,
and Marahiel, M. A.
(1999)
Cell Mol. Life Sci.
55,
423-436
|
| 32.
|
Kopito, R. R.
(1997)
Cell
88,
427-430
|
| 33.
|
Helekar, S. A.,
and Patrick, J.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
5432-5437
|
| 34.
|
Helekar, S. A.,
Char, D.,
Neff, S.,
and Patrick, J.
(1994)
Neuron
12,
179-189
|
| 35.
|
Chen, H.,
Kubo, Y.,
Hoshi, T.,
and Heinemann, S. H.
(1998)
FEBS Lett.
422,
307-310
|
| 36.
|
Tran, T. T.,
Dai, W.,
and Sarkar, H. K.
(2000)
J. Biol. Chem.
275,
35708-35714
|
| 37.
|
Shiraishi, S.,
Yokoo, H.,
Kobayashi, H.,
Yanagita, T.,
Uezono, Y.,
Minami, S.,
Takasaki, M.,
and Wada, A.
(2000)
Neurosci. Lett.
293,
211-215
|
| 38.
|
Shiraishi, S.,
Yanagita, T.,
Kobayashi, H.,
Uezono, Y.,
Yokoo, H.,
Minami, S. I.,
Takasaki, M.,
and Wada, A.
(2001)
J. Pharmacol. Exp. Ther.
297,
657-665
|
| 39.
|
Riordan, J. R.,
Deuchars, K.,
Kartner, N.,
Alon, N.,
Trent, J.,
and Ling, V.
(1985)
Nature
316,
817-819
|
| 40.
|
Kartner, N.,
Riordan, J. R.,
and Ling, V.
(1983)
Science
221,
1285-1288
|
| 41.
|
Oellerich, M.,
Armstrong, V. W.,
Kahan, B.,
Shaw, L.,
Holt, D. W.,
Yatscoff, R.,
Lindholm, A.,
Halloran, P.,
Gallicano, K.,
Wonigeit, K.,
et al..
(1995)
Ther. Drug Monit.
17,
642-654
|
| 42.
|
Holt, D. W.,
Johnston, A.,
Kahan, B. D.,
Morris, R. G.,
Oellerich, M.,
and Shaw, L. M.
(2000)
Clin. Chem.
46,
872-874
|
| 43.
|
Cruz, F.,
and Wolf, A.
(2001)
Biochem. Pharmacol.
62,
129-139
|
| 44.
|
Lemaire, M.,
Bruelisauer, A.,
Guntz, P.,
and Sato, H.
(1996)
Cancer Chemother. Pharmacol.
38,
481-486
|
| 45.
|
Berden, J. H.,
Hoitsma, A. J.,
Merx, J. L.,
and Keyser, A.
(1985)
Lancet
1,
219-220
|
| 46.
|
de Groen, P. C.,
Aksamit, A. J.,
Rakela, J.,
Forbes, G. S.,
and Krom, R. A.
(1987)
N. Engl. J. Med.
317,
861-866
|
| 47.
|
Li, Z.,
Matsuoka, S.,
Hryshko, L. V.,
Nicoll, D. A.,
Bersohn, M. M.,
Burke, E. P.,
Lifton, R. P.,
and Philipson, K. D.
(1994)
J. Biol. Chem.
269,
17434-17439
|
| 48.
|
Nicoll, D. A.,
Longoni, S.,
and Philipson, K. D.
(1990)
Science
250,
562-565
|
| 49.
|
Nicoll, D. A.,
Quednau, B. D.,
Qui, Z.,
Xia, Y.-R.,
Lusis, A. J.,
and Philipson, K. D.
(1996)
J. Biol. Chem.
271,
24914-24921
|
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
B. Elbaz, A. Alperovitch, M. M. Gottesman, C. Kimchi-Sarfaty, and H. Rahamimoff
Modulation of Na+-Ca2+ Exchanger Expression by Immunosuppressive Drugs Is Isoform-Specific
Mol. Pharmacol.,
April 1, 2008;
73(4):
1254 - 1263.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Sabella, E. Faszewski, L. Himic, K. M. Colpitts, J. Kaltenbach, M. M. Burger, and X. Fernandez-Busquets
Cyclosporin A Suspends Transplantation Reactions in the Marine Sponge Microciona prolifera
J. Immunol.,
November 1, 2007;
179(9):
5927 - 5935.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. R. Romero, A. Rivera, V. Lanca, M. D. P. Bicho, P. R. Conlin, and D. A. Ricupero
Na+/Ca2+ Exchanger Activity Modulates Connective Tissue Growth Factor mRNA Expression in Transforming Growth Factor {beta}1- and Des-Arg10-kallidin-stimulated Myofibroblasts
J. Biol. Chem.,
April 15, 2005;
280(15):
14378 - 14384.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2002 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|